Screener
Theravance Biopharma TBPH Investing Cash Flow
Investing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Theravance Biopharma in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.
The source filing: Theravance Biopharma’s 10-Q, filed August 11, 2026.
- Filed
- Aug 11, 2026, 8:00 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001104659-26-093773
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Purchases of property and equipment | — | (34) |
| Purchases of marketable securities | (145,306) | (58,542) |
| Maturities of marketable securities | 137,496 | 52,950 |
| Net cash used in investing activities | (7,810) | (5,626) |
| Financing activities | ||
| Proceeds from the sale of ordinary shares | — | 20 |
| Proceeds from option exercises | 1,378 | — |
| Repurchase of shares to satisfy tax withholding | (7,922) | (1,377) |
Item 1. Financial Statements (unaudited)
FAQ
- What is Theravance Biopharma's investing cash flow?
- Theravance Biopharma (TBPH) reported investing cash flow of -$60.4M in Q2 2026.
- How has Theravance Biopharma's investing cash flow changed year-over-year?
- Theravance Biopharma's investing cash flow decreased by 66.6% year-over-year, from -$36.26M to -$60.4M.
- What does investing cash flow mean?
- Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.
Ask your AI about Theravance Biopharma's investing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude